盘中“狂飙”130%，药捷安康市值逼近千亿港元

Core Insights - The stock price of Yaojie Ankang surged over 130% on September 12, reaching a peak of 251.4 HKD, with a closing increase of approximately 77.09%, bringing its market capitalization close to 100 billion HKD [1] - Yaojie Ankang, established in 2014, went public in June 2023, raising 161 million HKD through the issuance of 15.28 million shares at an IPO price of 13.15 HKD [1] - The company focuses on innovative small molecule therapies for oncology and inflammatory diseases, with its core product being Tiengogatinib, the first FGFR inhibitor in the registration clinical stage for treating recurrent or refractory cholangiocarcinoma [1][2] Company Developments - The significant rise in Yaojie Ankang's stock price is attributed to the recent announcement regarding Tiengogatinib's II phase clinical trial for HR+ and HER2- metastatic breast cancer, which received clinical implicit approval from the NMPA on September 10, 2025 [2] - Tiengogatinib has also been recognized as a breakthrough therapy for cholangiocarcinoma by the NMPA and has received fast track designation from the FDA for both cholangiocarcinoma and metastatic castration-resistant prostate cancer [2] Financial Performance - Yaojie Ankang has not yet commercialized any products, resulting in no profitability; in 2023, the company reported revenues of 1.181 million HKD and a net loss of 343 million HKD [3] - For 2024, the company anticipates zero revenue and a net loss of 275 million HKD; in the first half of 2025, it reported other income of 3.6 million HKD, a 65.1% year-over-year decline, and a net loss of 123 million HKD, slightly narrowing from 160 million HKD in the previous year [3] - Research and development expenses for the first half of 2025 were 98.43 million HKD, down 30.1% year-over-year [3]